Kimlinger TK - Search Results

1

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Kumar S, et al. Among authors: kimlinger tk. Blood. 2004 Aug 15;104(4):1159-65. doi: 10.1182/blood-2003-11-3811. Epub 2004 May 6. Blood. 2004. PMID: 15130943 Free article.

2

Expression of CD52 on plasma cells in plasma cell proliferative disorders.

Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Kumar S, et al. Among authors: kimlinger tk. Blood. 2003 Aug 1;102(3):1075-7. doi: 10.1182/blood-2002-12-3784. Epub 2003 Apr 24. Blood. 2003. PMID: 12714489 Free article.

3

Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.

Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Kimlinger T, et al. Haematologica. 2006 Aug;91(8):1033-40. Epub 2006 Jul 25. Haematologica. 2006. PMID: 16870555

4

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. Alsayed Y, et al. Blood. 2007 Apr 1;109(7):2708-17. doi: 10.1182/blood-2006-07-035857. Blood. 2007. PMID: 17119115 Free PMC article.

5

Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.

Kimlinger T, Witzig TE. Kimlinger T, et al. Bone Marrow Transplant. 1997 Mar;19(6):553-6. doi: 10.1038/sj.bmt.1700697. Bone Marrow Transplant. 1997. PMID: 9085734

6

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.

Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. Kumar S, et al. Leukemia. 2005 Aug;19(8):1466-70. doi: 10.1038/sj.leu.2403823. Leukemia. 2005. PMID: 15959533

7

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Ramakrishnan V, et al. Among authors: kimlinger tk. Oncogene. 2010 Feb 25;29(8):1190-202. doi: 10.1038/onc.2009.403. Epub 2009 Nov 23. Oncogene. 2010. PMID: 19935717 Free PMC article.

8

R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.

Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. Kline MP, et al. Among authors: kimlinger tk. Exp Hematol. 2008 May;36(5):568-76. doi: 10.1016/j.exphem.2008.01.003. Epub 2008 Mar 17. Exp Hematol. 2008. PMID: 18346839 Free PMC article.

9

Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.

Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Ramakrishnan V, et al. Among authors: kimlinger tk. Am J Hematol. 2012 Mar;87(3):277-83. doi: 10.1002/ajh.22263. Epub 2011 Dec 21. Am J Hematol. 2012. PMID: 22190165 Free PMC article.

10

A phase II trial of imatinib in patients with refractory/relapsed myeloma.

Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE. Dispenzieri A, et al. Leuk Lymphoma. 2006 Jan;47(1):39-42. doi: 10.1080/10428190500271269. Leuk Lymphoma. 2006. PMID: 16321825 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters